Stocks · News reference
LeMaitre Vascular Lowers FY2026 GAAP EPS Guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 Est; Lowers FY2026 Sales Guidance from $277.000M-$283.000M to $274.300M-$278.300M vs $279.948M Est
LeMaitre Vascular (NASDAQ:LMAT) lowers FY2026 GAAP EPS guidance from $2.93-$3.08 to $2.84-$2.94 vs $2.97 analyst estimate. Lowers FY2026 sales outlook from $277.000 million-$283.000 million to $274.300 million-$278.300
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 4, 2026, 8:25 PM
- Checked
- Aug 4, 2026, 8:25 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
LeMaitre Vascular shares are trading lower after the company reported worse-than-expected Q2 financial results and lowered its FY2026 GAAP EPS and FY2026 sales guidance.
Read original at benzinga8-K filing — LEMAITRE VASCULAR INC (LMAT)
Filed: 2026-08-04 AccNo: 0001193125-26-332982 Size: 383 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarLeMaitre Vascular Sees Q4 GAAP EPS $0.75-$0.81 vs $0.78 Est; Sees Sales $71.100M-$73.100M vs $72.745M Est
LeMaitre Vascular (NASDAQ:LMAT) is looking for Q4 GAAP EPS of $0.75-$0.81 vs $0.78 analyst estimate. sees sales of $71.100 million-$73.100 million vs $72.745 million analyst estimate.
Read original at benzinga